Biosig Technologies (STEX) vs. Its Competitors Head to Head Review

Biosig Technologies (NASDAQ:STEX) is one of 29 publicly-traded companies in the “Surgical, Medical, And Dental Instruments And Supplies” industry, but how does it weigh in compared to its competitors? We will compare Biosig Technologies to similar businesses based on the strength of its dividends, profitability, risk, institutional ownership, analyst recommendations, valuation and earnings.

Institutional & Insider Ownership

7.2% of Biosig Technologies shares are held by institutional investors. Comparatively, 22.5% of shares of all “Surgical, Medical, And Dental Instruments And Supplies” companies are held by institutional investors. 52.7% of Biosig Technologies shares are held by company insiders. Comparatively, 18.1% of shares of all “Surgical, Medical, And Dental Instruments And Supplies” companies are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Valuation & Earnings

This table compares Biosig Technologies and its competitors top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Biosig Technologies	$40,000.00	-$10.33 million	-1.59
Biosig Technologies Competitors	$59.54 million	-$32.15 million	4.35

Biosig Technologies’ competitors have higher revenue, but lower earnings than Biosig Technologies. Biosig Technologies is trading at a lower price-to-earnings ratio than its competitors, indicating that it is currently more affordable than other companies in its industry.

Analyst Ratings

This is a breakdown of current ratings and price targets for Biosig Technologies and its competitors, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Biosig Technologies	1	0	0	0	1.00
Biosig Technologies Competitors	77	78	158	6	2.29

As a group, “Surgical, Medical, And Dental Instruments And Supplies” companies have a potential upside of 38.17%. Given Biosig Technologies’ competitors stronger consensus rating and higher probable upside, analysts plainly believe Biosig Technologies has less favorable growth aspects than its competitors.

Volatility and Risk

Biosig Technologies has a beta of 1.5, indicating that its share price is 50% more volatile than the S&P 500. Comparatively, Biosig Technologies’ competitors have a beta of 1.76, indicating that their average share price is 76% more volatile than the S&P 500.

Profitability

This table compares Biosig Technologies and its competitors’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Biosig Technologies	N/A	N/A	-64.96%
Biosig Technologies Competitors	-672.41%	-133.75%	-59.01%

Summary

Biosig Technologies competitors beat Biosig Technologies on 8 of the 12 factors compared.

About Biosig Technologies

BioSig Technologies, Inc., together with its subsidiaries, operates as medical device company. The company’s proprietary product includes precise uninterrupted real-time evaluation of electrograms electrophysiology (PURE EP) system, a signal processing platform that combines hardware and software to address known challenges associated to signal acquisition that enables electrophysiologists to see signals and analyze in real-time. It also focuses on enhancing intracardiac signal acquisition and diagnostic information for the procedures of atrial fibrillation, as well as is designed to address long-standing limitations that slow and disrupt cardiac catheter ablation procedures. The company has a research agreement with University of Minnesota to develop novel therapies to treat sympathetic nervous system diseases; and a strategic collaboration with the Mayo Foundation for Medical Education and Research to develop an AI-and machine learning software solution for PURE EP systems. BioSig Technologies, Inc. was incorporated in 2009 and is headquartered in Westport, Connecticut.